Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · KisspeptinSupported
Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche.
A prospective, well-structured diagnostic study (n=96) with ROC and decision-curve analysis addressing a genuine clinical bottleneck. Note this concerns endogenous kisspeptin-10 measured as a biomarker, not administered peptide — it speaks to kisspeptin biology, not to any use protocol. Single-population Indian cohort with moderate sensitivity (72.7%); the cut-off needs external validation before clinical adoption.
Clinica chimica acta; international journal of clinical chemistryn=—HumanJan 1, 2027 - Study · KisspeptinWeak / none
The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54.
This in vitro pharmacology directly compares kisspeptin-10 and kisspeptin-54 against a synthetic analog, relevant background for how different kisspeptin forms behave at the receptor. Findings are cell-based only and focused on drug-discovery characterization, including the tachyphylaxis (desensitization) seen with continuous stimulation. Useful context rather than a human protocol signal.
Molecular and cellular endocrinologyn=—In vitroOct 1, 2026 - Study · KisspeptinMixed
Kisspeptin System: A Modulator of Neuroinflammation and Behaviour in Temporal Lobe Epileptic Rats.
This adds a neuroinflammation angle to a peptide usually discussed for its reproductive-axis role, and the design is reasonably complete for preclinical work: expression mapping across three brain regions, cellular localisation, then an intervention arm with behavioural readout. The constraints are the usual ones — a single chemically induced rat model, group sizes not stated in the abstract, and effects measured as cytokine and histology changes rather than seizure outcomes, which the abstract does not report. Correlation between inflammatory markers and kisspeptin expression is not mechanism. It is a hypothesis worth watching, and nothing in it supports use in people.
Molecular neurobiologyn=—AnimalSep 1, 2026 - Study · KisspeptinMixed
Follicular kisspeptin-VEGF axis in polycystic ovary syndrome and ovarian hyperstimulation syndrome.
This is measurement of the body's own kisspeptin inside the follicle, not administration of a kisspeptin analogue, so it speaks to the peptide's reproductive biology rather than to any reported protocol. The design is retrospective and cross-sectional with 30 women per group, and the odds ratios for kisspeptin-54 and VEGF are very close to 1.0 per unit, which is why the authors themselves stop short of a predictive claim. The stepwise gradient across groups is the durable observation here; causal direction cannot be established from this data, since heavy ovarian stimulation could plausibly raise these levels rather than the reverse.
Journal of assisted reproduction and geneticsn=—HumanAug 28, 2026 - Study · KisspeptinWeak / none
Seminal Plasma Kisspeptin-1 and Kisspeptin-54 Levels Are Associated With Semen Parameters and Oxidative Stress in Male Infertility.
An observational biomarker study, not an intervention: it measures endogenous kisspeptin in seminal plasma rather than administering anything. The dose-response-like gradient across infertility severity and the link to oxidative stress markers are internally consistent, but 50 participants from a single IVF center is a thin base, and correlation studies of this size often fail to replicate. Relevant context for kisspeptin's role in the reproductive axis; the biomarker claim awaits validation in larger cohorts.
Clinical endocrinologyn=—HumanAug 7, 2026 - Study · KisspeptinSupported
Chronic Subcutaneous Kisspeptin-10 Stimulates Gonadotropin Secretion for 12 Days in Healthy Men.
The finding that matters is the contrast between the two chronic schedules: continuous exposure lost the gonadotropin effect within five days while intermittent dosing held it for twelve, which is consistent with what is known about pulsatile control of the reproductive axis. The retained response to a terminal bolus is direct evidence against receptor desensitisation on the intermittent schedule. Fifteen men across three sub-studies is a small sample, and these are hormone measurements in healthy volunteers rather than clinical outcomes, but the dosing-schedule question is a real one and this study answers it cleanly.
European journal of endocrinologyn=—HumanAug 4, 2026 - Study · KisspeptinWeak / none
Kisspeptin Signaling Suppresses HRasG12V-induced Tumor Growth and Metastasis by Inhibiting SP1-dependent N-cadherin Expression in NIH3T3 Cells.
An in vitro and mouse-model study identifying a metastasis-suppressive mechanism for kisspeptin signaling in HRAS-driven cells. As mechanistic bench science it is early-stage evidence about kisspeptin biology, well upstream of any clinical inference.
Anticancer researchn=—In vitroAug 1, 2026 - Study · KisspeptinWeak / none
Kisspeptin-54 confers renal protection in diabetic nephropathy by ameliorating endothelial permeability through ZEB1 inhibition.
This is a preclinical study in which kisspeptin-54 was directly administered to diabetic mice and applied to cultured kidney endothelial cells, with reported effects on barrier function and markers of renal injury. As mechanistic animal and in-vitro work, the evidence is early-stage and not yet tested in humans. It is a genuine kisspeptin intervention study, so it is relevant, though findings should be read as preliminary.
Tissue & celln=—AnimalAug 1, 2026 - Study · KisspeptinWeak / none
Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory axis.
This in vitro study applies exogenous kisspeptin-10 to ovarian cancer cell lines and reports anti-metastatic signaling effects. It is cell-culture only, so it is an early mechanistic observation rather than evidence in animals or humans. A genuine kisspeptin-as-agent study but at the weakest tier of evidence.
Cytotechnologyn=—In vitroAug 1, 2026 - Study · KisspeptinWeak / none
Kisspeptin.
A brief overview article centered on kisspeptin, a tracked peptide involved in reproductive hormone regulation. No abstract detail is available, so scope and depth are unclear, but the topical focus is directly on the peptide. Likely background reference material.
Trends in endocrinology and metabolism: TEMn=——Jul 15, 2026 - Study · KisspeptinWeak / none
Kisspeptin-54 attenuates acute lung injury in septic mice through AMPK-mediated suppression of NLRP3 inflammasome.
A mouse study reporting that exogenous kisspeptin-54 was associated with improved survival and reduced sepsis-induced lung injury via AMPK-mediated suppression of the NLRP3 inflammasome. Findings are preclinical and in a non-reproductive context, so they should not be extrapolated to humans. Directly administers a tracked peptide.
Neuropeptidesn=—AnimalJun 23, 2026 - Study · KisspeptinWeak / none
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
This study is not a clinical or pharmacological investigation — it is a doping-control analytical methods paper, and should be read as such. Researchers developed and validated a streamlined workflow capable of detecting 54 prohibited substances, including BPC-157 and TB-500, across dried blood spots, serum, and plasma using a single microextraction step followed by liquid chromatography coupled with high-resolution mass spectrometry. The analytical performance was satisfactory by laboratory standards: detection limits ranged from 0.05–1.25 ng/mL, no carry-over was observed, and matrix effects were modest (5–33%). Notably, dried blood spot matrices preserved all compounds for the full study duration under non-refrigerated conditions — a meaningful practical advantage for anti-doping sample logistics. For readers tracking BPC-157 and TB-500 specifically: the stability data are striking. Both peptides showed complete degradation in serum within one week at room temperature or refrigerator temperature — a finding with direct implications for detection windows in anti-doping contexts. Dried matrices retained detectability throughout. This paper contributes nothing to the...
The Analystn=——Jun 22, 2026 - Study · KisspeptinWeak / none
Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.
This is a direct human study administering kisspeptin-10 by continuous infusion and tracking reproductive hormone responses. The sample is only three men and the design is exploratory physiology, so it is a preliminary signal rather than a controlled trial. Genuinely on-topic for how kisspeptin acts in humans, including the partial desensitization observed over 24 hours.
Hormones (Athens, Greece)n=——Jun 2, 2026